ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...
European Medical Journal2d
Treatment Advances in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...
CURE5h
First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...
ImmunityBio announces 1st dosing of rBCG in U.S. and 60 sites pending
ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...
Monthly Prescribing Reference22d
FDA Allows Use of Recombinant BCG Through Expanded Access Program
Providers who are unable to source TICE BCG will now be able to access rBCG ... “Our collaboration with the FDA and Serum Institute to ensure a reliable supply of this vital drug for bladder ...
Morningstar22d
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
BCG is one of the most widely used vaccines worldwide. However, because BCG is a biologic drug that uses benign bacteria, it is more complicated to make than many other types of drugs. Serum ...
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...
Targeted Oncology1d
EAP Enhances Access to Cretostimogene Grenadenorepvec
An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the ...